PHARMING GROUP NV (PHGN.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:PHGN - NL0010391025 - Common Stock
PHGN.DE Key Statistics, Chart & Performance
The current stock price of PHGN.DE is 1.605 EUR. In the past month the price increased by 6.93%.
PHGN.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 65.13 | 42.70B | ||
| 1AE.DE | ARGENX SE | 65.22 | 42.77B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.72B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.71B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.64B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.88B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.87B | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| NANO.PA | NANOBIOTIX | N/A | 856.31M | ||
| IVA.PA | INVENTIVA SA | N/A | 782.22M | ||
| 6IV.DE | INVENTIVA SA | N/A | 753.57M | ||
| PHIL.MI | PHILOGEN SPA | 20 | 666.67M |
Related stock screener links
About PHGN.DE
Company Profile
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 426 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Company Info
PHARMING GROUP NV
Darwinweg 24
Leiden ZUID-HOLLAND NL
Employees: 404
Phone: 31715247400
PHARMING GROUP NV / PHGN.DE FAQ
What does PHGN do?
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 426 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Can you provide the latest stock price for PHARMING GROUP NV?
The current stock price of PHGN.DE is 1.605 EUR. The price increased by 6.08% in the last trading session.
Does PHGN stock pay dividends?
PHGN.DE does not pay a dividend.
What is the ChartMill rating of PHARMING GROUP NV stock?
PHGN.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is PHARMING GROUP NV worth?
PHARMING GROUP NV (PHGN.DE) has a market capitalization of 109.97M EUR. This makes PHGN.DE a Micro Cap stock.
Can you provide the upcoming earnings date for PHARMING GROUP NV?
PHARMING GROUP NV (PHGN.DE) will report earnings on 2026-03-11, after the market close.
What is the ownership structure of PHARMING GROUP NV (PHGN.DE)?
You can find the ownership structure of PHARMING GROUP NV (PHGN.DE) on the Ownership tab.
PHGN.DE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to PHGN.DE.
PHGN.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PHGN.DE. PHGN.DE has an average financial health and profitability rating.
PHGN.DE Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.03% | ||
| ROA | 0.02% | ||
| ROE | 0.04% | ||
| Debt/Equity | 0.46 |
PHGN.DE Forecast & Estimates
14 analysts have analysed PHGN.DE and the average price target is 2.01 EUR. This implies a price increase of 25.2% is expected in the next year compared to the current price of 1.605.
For the next year, analysts expect an EPS growth of 234.87% and a revenue growth 26.31% for PHGN.DE